Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The invention pertains to a method for predicting a manifestation of an outcome measure of a cancer patient based on a tumor DNA containing tissue sample from the cancer patient, comprising, firstly, determining an existence of a sequence variation within segments of at least two genes of the tumor DNA as Present, if at least one significant sequence variation can be determined, or as Absent, if no significant sequence variation can be determined, wherein the at least two genes of the tumor DNA are associated with the outcome measure of the patient; secondly, combining the existence of sequence variations of the at least two genes using a logical operation (prediction function), and thirdly, predicting based on the results of the logical operation the manifestation of an outcome measure of the patient.

Abstract: The invention pertains to a method for predicting a manifestation of an outcome measure of a cancer patient based on a tumor DNA containing tissue sample from the cancer patient, comprising, firstly, determining an existence of a sequence variation within segments of at least two genes of the tumor DNA as Present, if at least one significant sequence variation can be determined, or as Absent, if no significant sequence variation can be determined, wherein the at least two genes of the tumor DNA are associated with the outcome measure of the patient; secondly, combining the existence of sequence variations of the at least two genes using a logical operation (prediction function), and thirdly, predicting based on the results of the logical operation the manifestation of an outcome measure of the patient.

Abstract: The invention relates to a method for determining prognosis of subjects with ovarian carcinoma using a biological sample comprising genomic tumor DNA isolated from the subject. According to the invention, the method comprises the steps of: determining the methylation status of a CpG dinucleotide in a target sequence that is selected from the group consisting of the target sequences as referred to by name in Table 1 in a biological sample isolated from a subject; and deducing from the determined methylation status of the target sequence the prognosis of subject with ovarian carcinoma. The improved prognosis determination of the subject with ovarian carcinoma enables the improved treatment of the said patient.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the abundance of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in tables 1 to 13 is measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from tissue of prostate tumors, which code for gene products or parts thereof and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from normal pancreatic tissue, which code for gene products or portions thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from breast tumor tissue, which code for gene products or parts thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: The disclosed synthesis system is based on the idea of designing a synthesis and treatment procedure, substrates and anchor groups which enable biomolecules to be simultaneously produced in an entirely automatic manner. By using a pipetting robot to dispense the reagents, the reaction column can be arranged in a format suitable for subsequent treatment. For a pipetting robot to carry out even water-sensitive or air-sensitive synthesis protocols, certain structural measures must be taken. The operation principle of the automaton and the synthesis sequence are described below as an example of a possible solution. The automaton can work with conventional substrates and reagents. Handling, however, is simplified by new, specially adapted substrates and anchor groups. A special, simultaneous purification and aliquot portioning process improves product quality and makes the device easier to use.

Abstract: Human nucleic acid sequences—mRNA, cDNA, genomic sequences—from endometrial tumor tissue, which code for gene products or portions thereof, and their use, are described. In addition, the polypeptides that can be obtained by way of the sequences and their use are described.

Abstract: The invention relates to a process for detecting differential gene expressions and new nucleic acid sequences that can be obtained by this process.

Abstract: The invention relates to human nucleic acid sequences—mRNA, cDNA, genome sequences—of ovarian tumour tissue, which code for gene products or parts of these products, and to their use. The invention also relates to the polypeptides obtained by way of these sequences and to the use of same.

Abstract: The sequencing and analysis of the complete nucleotide sequence of symbiotic plasmid pNGR234a isolated from Rhizobium sp. NGR234. The complete sequence of pNGR234a is presented. The analysis includes the identification of a number of novel ORFs and the proteins expressible therefrom which have been ascribed putative functions.

Abstract: The disclosed synthesis system is based on the idea of designing a synthesis and treatment procedure, substrates and anchor groups which enable biomolecules to be simultaneously produced in an entirely automatic manner. By using a pipetting robot to dispense the reagents, the reaction column can be arranged in a format suitable for subsequent treatment. For a pipetting robot to carry out even water-sensitive or air-sensitive synthesis protocols, certain structural measures must be taken. The operation principle of the automated and the synthesis sequence are described below as an example of a possible solution. The automation can work with conventional substrates and reagents. Handling, however, is simplified by new, specially adapted substrates and anchor groups. A special, simultaneous purification and aliquot portioning process improves product quality and makes the device easier to use.

Abstract: The sequencing and analysis of the complete nucleotide sequence of symbiotic plasmid pNGR234a isolated from Rhizobium sp. NGR234. The complete sequence of pNGR234a is presented. The analysis includes the identification of a number of novel ORFs and the proteins expressible therefrom which have been ascribed putative functions.

Abstract: The invention is drawn to a method of DNA sequencing using labeled nucleotides that do not act as chain elongation inhibitors where the label is removed or neutralized for the sequential addition of non-labeled nucleotides.

Abstract: A device for solid phase sequencing of nucleic acid segments comprises a plurality of sequencing blocks for storaging and processing n nucleic acid fragments immobilized on carrier segments or in homogenous phase during a sequencing process, each of a sample dosing device for immobilizing n labeled nucleic acid samples from the sequencing blocks onto areas of a carrier matrix in a simultaneous fashion and including a capillary holder and a plurality of capillaries corresponding to the number n of different nucleic acid samples to be sequences and arranged according to the distribution of the reaction vessels with a distance between capillary orifices from the capillary holder greater than a depth of the reaction vessels, a plurality of carrier holders for fixing carrier matrices in a predetermined position during the immobilization of the nucleic acid samples with the sample dosing device and each having a recess corresponding to respective dimensions of the carrier matrix and a plurality of bores with a numb

Abstract: A process for solid phase sequencing of nucleic acid fragments is disclosed. The object of the invention is to provide a sequencing process which enables the simultaneous sequencing of large amounts of long and short nucleic acid fragments and which is optionally automated. Thus, a solid support combining mechanical stability, anion exchange characteristics, and chemical elution of nucleic acids off the support is used. Immobilized nucleic acid fragments are chemically modified and subsequently the nucleic acid backbone is cleaved and simultaneously or subsequently said fragments are eluted by chemical means. The present invention is applied to molecular biology and gene technology.